Management of neuroendocrine tumours

Clinical Oncology

Volumn 11, Issue 5, 1999, Pages 295-302

  Reed, N S ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; SOMATOSTATIN DERIVATIVE;

ARTIFICIAL EMBOLISM; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; IMAGING; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS;

EID: 0032707478     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.1999.9072     Document Type: Review

References (80)

1. Pearse AGE. The cytochemistry and ultrastruture of polypeptide hormone-producing cells (the APUD series) and embryological, physiological and pathological implications of the concept. J Histochem Cytochem 1969;17:303.
2. Pearse AGE. Common cytochemical and ultrastructural characteristics of cells producing hormones (the APUD series) and their relevance to thyroid and ultimobranchial cells and calcitonin. Proc R Soc Eond 1968; 170-1.
3. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171-90.
4. Thomas RM, Sobin EH. Gastrointestinal cancer. Cancer 1995;75:154-70.
5. Goodwin DJ. Carcinoid tumours; an analysis of 2837 cases. Cancer 1975;36:560-9.
6. Saad ME, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 1984;63:319-42.
7. Correa P, Chen VW. Endocrine gland cancer. Cancer 1995;75:338-52.
8. Eriksson B, Arnberg H, Oberg K, et al. Chromogranins new sensitive markers for neuroendocrine tumours. Acta Oncol 1989;28:325-9.
9. O'Connor DT, Deftos EJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145-51.
10. Schurmann G, Raeth U, Wiedenmann B. Serum chromogranin A in the diagnosis and follow up of neuroendocrine tumours of the gastro-entero-pancreatic tract. World J Surg 1992; 16:697-702.
11. Meijer WG, Kema IP, Willemse PHB, et al. Platelet serotonin is the most sensitive marker for diagnosis of carcinoid tumours. Proc ASCO 1998:Abstr 1143.
12. Morrison ID, Reznek RH, Bomanji JB, et al. Imaging of gastrointestinal endocrine tumours. In: Sheaves R, Jenkins P, Wass JA, editors. Clinical endocrine oncology. Eondon: Blackwell, 1997:359-68.
13. Thoeni RF, Blankenberg F. Pancreatic imaging: computed tomography and magnetic resonance imaging. Radiol Clin North Am 1993;31:1085-113.
14. Aspestrand F, Kolmannskog F, Jacobsen M. MR imaging and angiography in pancreatic apudomas. Acta Radiol 1993;34:468-73.
15. Palazzo E, Roseau G, Chaussade S, et al. Contribution of ultrasound endoscopy in the diagnosis of localisation. Ann Chir 1993;47:419-24.
16. Costello P, Lobree S. Subsecond scanning makes CT even faster. Diagn Imaging. 1996;76-9.
17. Eriksson B, Bergstrom M, Eilja A, et al. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumours. Acta Oncol 1993;32:189-96.
18. Ohta H, Yamamoto K, Endo K, et al. A new imaging agent for medullary thyroid cancer. J Nucl Med 1984;25:323-5.
19. 99mTcMDP: an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988;29:33-8.
20. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localisation of phaeochromocytoma. N Engl J Med 1981;305:12-14.
21. Shapiro B, Copp JE, Sisson JC. Iodine-131 metaiodobenzylguanidine for the location of suspected phaeochromocytoma: experience in 400 cases. J Nucl Med 1985;26:576-8.
22. Hoefnagel C. Radionuclide therapy revisited. Eur J Nucl Med 1991;18:408.
23. Vinik AI, McLeod MK, Fig LM, et al. Clinical features, diagnosis and localisation of carcinoid tumours and their management. Gastroenterol Clin North Am 1989;18:865-96.
24. Reubi JC, Hacki WH, Lamberts SWL. Hormone producing gastro-intestinal tumours contain high density of somatostatin receptors. J Clin Endocrinol Metab 1987;65:1127-34.
25. Reubi JC, Kvols L, Krenning EP, et al. Distribution of somatostatin receptors in normal and tumour tissue. Metabolism. 1990;39:78-81.
26. Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabelling, purification, biological activity, and in vivo application in animals. J Nucl Med 1990;31:1501-9.
27. Reubi JC, Maurer R. Autoradiographic mapping of somatostatin receptors in the rat CNS and pituitary. Neuroscience 1985;15:1183-93.
28. Krenning EP, Bakker WH, Breeman WAP, et al. Eocalisation of endocrine related tumours with radioiodinated analogue of somatostatin. Eancet 1989;i:242-4.
29. 123I-Tyr-]Octreotide. Eur J Nucl Med 1993;20:716-31.
30. Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. Nucl Med Annu 1995; 1-50.
31. 111-In-DTPA-octreotide receptor scintigraphy in GEP tumours a comparison of trials. Update-Octreoscan 1994;1:32-41.
32. Termanini B, Gibril G, Reynolds JC, et al. Value of somatostatin scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335-17.
33. Eebtahi R, Cadiot G, Sarda E, et al. Clinical impact of somatostatin receptor scintigraphy in management of patients with neuroendocrine gastroenteropancreatic tumours. J Nucl Med 1997;38:853-8.
34. Zeiger MA, Shawker TH, Norton JA. Use of intraoperative ultrasonography to localise islet cell tumours. World J Surg 1993; 17:448-54.
35. Ahlman H, Wangberg B, Tisell EE, et al. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Cancer 1995;81:1144-9.
36. Moertel CG, Sauer WG ,Dockerty MB. Life history of the carcinoid tumour of the small intestine. Cancer 1961;14:901-12.
37. Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumours: an analysis of 103 patients with regard to tumour localisation, hormone production and survival. Ann Surg 1987;206:115-25.
38. Eamberts SWJ, Van der Eely A-J, De Herder WW, et al. Octreotide. N Engl J Med 1996;334:246-54.
39. Evers BM, Parekh D, Townsend CM, et al. Somatostatin and its analogues in the treatment of cancer: a review. Ann Surg 1991;213(3): 190-8.
40. Serially AV. Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977-85.
41. Saltz E, Trochanowski B, Buckley M, et al. Octreotide as an anti-neoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumours. Cancer 1993; 72:244-8.
42. Chaudry A, Kvols E. Advances in the use of somatostatins in the management of endocrine tumours. Curr Opin Oncol 1996;8:44-8.
43. Eriksson B, Skogseid B, Eundqvist G, et al. Medical treatment and long term survival in a prospective study of 84 patients with endocrine pancreatic tumours. Cancer 1990;65:1883-90.
44. Oberg K. Treatment of neuroendocrine tumours. Cancer Treat Rev 1994;20:331-55.
45. Kvols E, Reubi JC, Honsberger U, et al. The presence of somatostatin receptors in malignant neuroendocrine tumour tissue predicts responsiveness to octreotide. Yale J Biol Med 1992;65:505-18.
46. Moertel CG, Johnson CM, McCusick MA, et al. The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
47. Oberg K, Norheim I, Lind E, et al. Treatment of Malignant carcinoid tumours with human leukocyte Interferon: long term results. Cancer Treat Rep 1986;70:1297-304.
48. Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumours with recombinant interferon-alpha 2a. Cancer 1993;72:3099-105.
49. Valimaki M, Jarvinen H, Salmela P, et al. Is the treatment of metaststic carcinoid with interferon not as successful as suggested? Cancer 1991;67:547-9.
50. Oberg K, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumours. Acta Oncol 1989;28:425-31.
51. Hansen EE, Schrumpf E, Kolvenstvedt AN, et al. Recombinant human alpha2-interferon in the treatment of malignant metastatic mid-gut carcinoid tumours. J Interferon Res 1987;7:735.
52. Oberg K. Biology, diagnosis and treatment of neuroendocrine tumours of the gastrointestinal tract. Curr Opin Oncol 1994;6:441-51.
53. Moertel CG. An odyssey in the land of small tumours. J Clin Oncol 1987;5:1503-22.
54. Kvols EK, Buck M. Chemotherapy of endocrine malignancies. Semin Oncol 1987; 14:343-53.
55. Haller DG. Endocrine tumours of the gastrointestinal tract. Curr Opin Oncol 1994;6:72-6.
56. Seymour MT, Slevin ME. Chemotherapy for malignant neuroendocrine tumours. In: Sheaves R, Jenkins P, Wass JA, editors. Clinical endocrine oncology. Eondon: Blackwell, 1997:426-30.
57. Moertel CG, Eefkopoulo M, Eipsitz M, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
58. Moertel CG, Kvols EK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 1991;68:227-32.
59. Averbuch SD, Steakley CS, Young RC, et al. Malignant phaeochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 1988;109:267-73.
60. Yakendji K, Rougier P, Ducreux M, et al. Efficacy of the combination of etoposide and cisplatinum in the treatment of neuroendocrine digestive carcinoma. Proc ECCO 1995:563.
61. Carnaghi C, Bajetta E, Di Bartolomeo M, et al. The medical treatment of neuroendocrine tumours: the experience of the Italian Trials in Medical Oncology (ITMO) Group. Proc ESMO 1996:228P.
62. Hatton MQF, Reed NS. Chemotherapy for neuroendocrine tumours: the Beatson Oncology experience. Clin Oncol 1997;9:385-9.
63. Tiensuu-Jansson E, Ronnblom E, Ahlstrom H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumours: a randomised trial. Ann Oncol 1992;3:635-8.
64. Andreyev J, Rigg A, Scott-Mackie P, et al. Infusional 5-fluorouracil with alpha Interferon as a palliative treatment for patients with symptomatic malignant neuroendocrine tumours. Proc ECCO 1995:560.
65. Diaco DS, Hajarizadeh H, Mueller CR, et al. Treatment of metastatic carcinoid using multimodality therapy of octreotide acetate, intra arterial chemotherapy and hepatic chemoembolisation. Am J Surg 1995;169:523-8.
66. Mavligit GM, Pollock RE, Evans HE, et al. Durable hepatic regression after arterial chemoembolisation-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver. Cancer 1993;72:375-80.
67. Soulen MC. Chemoembolisation of hepatic malignancies. Oncology 1994;8(4):77-84.
68. Ruszniewski P, Rougier P,Roche A. Hepatic artery chemoembolisation in patients with liver metastases of endocrine tumours. Cancer 1993;71:2624-30.
69. Cozzi PJ, Englund R, Morris DE. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumours. Cancer 1995;76:501-9.
70. Munke H, Schworer H, Stockmann F, et al. Treatment of hepatic metastasised carcinoids with percutaneous ethanol injection. Follow up of five cases. Tumor Diagn Ther 1997;18:133-7.
71. Gaitan-Gaitan A, Rider WD, Bush RS. Carcinoid tumour cure by irradiation. Int J Radiat Oncol Biol Phys 1975;1:9-13.
72. Keane TJ, Rider WD, Harwood AR, et al. Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumour. Int J Radiat Oncol Biol Phys 1981 ;7:1519-21.
73. Samlowski WE, Eyre HJ, Sause WT. Evaluation of the response of unresectable carcinoid tumours to radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:301-5.
74. Tennvall J, Ejungberg O, Ahren B, et al. Radiotherapy for unresectable endocrine pancreatic carcinomas. Eur J Surg Oncol 1992;18:73-6.
75. Chakravarthy A, Abrams RA. Radiation therapy in the management of patients with malignant carcinoid tumours. Cancer 1995;75:1386-90.
76. Sisson JC, Shapiro B, Bierwaltes WH, et al. Radiopharmaceutical treatment of malignant phaeochromocytoma. J Nucl Med 1984;25:197-206.
77. 161Tb-DTPA octreotide, a somatostatin analogue with potential for intra-operative scanning and radiotherapy. Eur J Nucl Med 1995;22:608-16.
78. Wiseman GA, Kvols EK. Therapy of neuroendocrine tumours with radiolabelled MIBG and somatostatin analogues. Semin Nucl Med 1995;25:272-8.
79. 111IN-DTPA-octreotide. Proc ECCO 1997:1230.
80. de Jong M, Bernard BF, De Bruin E, et al. Internalisation of radiolabelled [DTPA0]octreotide and [DOTAO,Tyr3]-octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998; 19:283-8.